Compare Gilead Sciences, Inc. (GILD) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Xpeng Inc - ADR — how do they compare? Gilead Sciences, Inc. trades at $151.38 (market cap $182.40B), while Xpeng Inc - ADR trades at $9.87 (market cap $9.16B). The key difference: Gilead Sciences, Inc. is far larger — about 19.9× Xpeng Inc - ADR's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Xpeng Inc - ADR for 80 Days on average.
| GILD | XPEV | |
|---|---|---|
Market Cap | $182.40B | $9.16B |
Volume | 4,469,821 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $28.07 |
52-Week Low | $116.74 | $9.25 |
Typical Hold Time | 111 Days | 80 Days |
Enterprise Value | $205.46B | $11.09B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
XPeng (XPEV) trades at $9.92, up 3.55% today, but remains in a bearish technical trend. The company shows mixed fundamentals with strong revenue growth to $76.72B in 2025 but persistent net losses. Recent Q2 2026 earnings missed expectations, though vehicle deliveries surged 65% quarter-over-quarter. Analyst consensus remains bullish with a $17.55 price target, representing 77% upside potential from current levels.
XPeng presents a high-risk, high-reward opportunity with significant growth potential in EVs and robotics, but profitability challenges and competitive pressures create substantial risk. The stock's current valuation at 0.81 P/S appears attractive if the company can achieve sustainable profitability, but investors face execution risk amid China's competitive EV market and global expansion challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
